Targeting the immune system has emerged as an encouraging strategy for a broad range of malignancies. In lymphoma, evidence of the expression of programmed death-1 (PD-1) and PD ligand 1 (PD-L1) has led to the development of a growing number of immune checkpoint inhibitors that are demonstrating promise in early clinical trials.
A new programme to boost research on cancers prevalent in Asia will give the region a stronger foothold in drug development, expedite drug approvals and improve patient access to innovative medications.
Genome sequencing has given rise to possibilities for targeted therapy in many diseases. By predicting who might respond to a particular therapy, based on their own cancer’s genetic profile, it is easier to select a treatment that is more likely to be effective, offer longer survival and keep quality of life high. Radha Chitale discussed the evolution and potential of personalized cancer care with Dr. William Nelson, director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, Maryland, US.
Extracted from a speech presented by Dr. Saunthari Somasundaram, president and medical director of the National Cancer Society of Malaysia, at the opening of the inaugural World Cancer Day Conference and Expo 2014, Kuala Lumpur, 22 February
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.
A second set of Choosing Wisely recommendations developed by the American Society of Hematology (ASH) were presented at the 56th ASH Annual Meeting & Exposition. The following list adds to the previous five tests, treatments and procedures that should be questioned by clinicians and patients under specific, indicated circumstances. [Blood 2014;124:3524-3528]
The US FDA granted accelerated approval to palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, as first-line endocrine therapy for postmenopausal women with oestrogen receptor (ER)-positive, HER2-negative metastatic breast cancer.